Sanofi agrees to license infectious disease assets to Evotec
Germany-based Evotec will also get licenses of a majority of infectious disease research portfolio and initiatives of Sanofi as per the terms of the transaction agreement. Sanofi has
French pharmaceutical company MITEM PHARMA has announced the acquisition of worldwide rights to DESFERAL (deferoxamine), an injectable medicine of major therapeutic interest (MITM) in haematology field, from Novartis.
The trial showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients treated with EPd compared with pomalidomide and dexamethasone (Pd) alone. ELOQUENT-3 is